GlassScriptPhysician profile
Robin L Corbett
NPI 1275528044
$13,127.34
in general payments reported to CMS, 2019-2025
30 companies · $2,264 in 2025
The $2,264 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,588 · 2020: $1,039 · 2021: $2,161 · 2022: $1,841 · 2023: $1,870 · 2024: $2,364 · 2025: $2,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,335 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,335.43 |
| Education | $162.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,933.09 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,551.22 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,257.86 | 2019-2024 | Xifaxan, Trulance |
| Celgene Corporation | $930.61 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $734.03 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $632.69 | 2021-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $538.36 | 2024-2025 | Zymfentra, Vegzelma |
| Ardelyx, INC. | $493.89 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $463.59 | 2022-2025 | Dupixent |
| Pfizer INC. | $440.82 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $375.92 | 2019-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $212.71 | 2020-2023 | |
| Lilly USA, LLC | $195.05 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $188.71 | 2020-2021 | |
| Braintree Laboratories, INC. | $187.59 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $164.48 | 2019-2022 | |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Ferring Pharmaceuticals INC. | $119.39 | 2019-2023 | Rebyota |
| Sandoz INC. | $97.02 | 2023-2024 | Hyrimoz |
| Medtronic, INC. | $85.41 | 2023-2025 | Pillcam, Gi Genius |
| Organon LLC | $79.29 | 2024-2025 | Renflexis, Hadlima |
| Genzyme Corporation | $75.46 | 2022-2025 | |
| Alfasigma USA, INC. | $56.73 | 2020 | |
| Fresenius Kabi USA, LLC | $47.18 | 2023-2024 | Idacio |
| Daiichi Sankyo INC. | $33.61 | 2019-2021 | |
| Boston Scientific Corporation | $19.16 | 2019 | |
| Novo Nordisk INC | $18.17 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $14.71 | 2024 | Voquezna |
| Romark Laboratories, Lc | $14.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.